Forest Bites At Stroke Clot Dissolver; Desmoteplase Could Have Nine-Hour Treatment Window
This article was originally published in The Pink Sheet Daily
Executive Summary
The company licenses U.S. and Canadian rights to Phase II plasminogen activator, derived from vampire bat saliva, from German firm PAION GmbH; desmoteplase is Forest’s first biologic product. The companies expect to initiate the rolling BLA submission as early as 2007.